表紙
市場調査レポート

黒色腫:医療機器のパイプライン分析

Melanoma - Pipeline Review, 2015

発行 GlobalData 商品コード 232257
出版日 ページ情報 英文 86 Pages
即納可能
価格
本日の銀行送金レート: 1USD=105.42円で換算しております。
Back to Top
黒色腫:医療機器のパイプライン分析 Melanoma - Pipeline Review, 2015
出版日: 2015年10月01日 ページ情報: 英文 86 Pages
概要

当レポートでは、世界各国の企業・医療機関などで開発中の、黒色腫 (メラノーマ) 向け診断機器のパイプライン製品情報について分析し、治験/製品開発の全体的な進行状況や、段階別・分野別・地域別の詳細動向、企業別・製品別の詳細情報 (治験の進行段階、開始/終了時期、認証見通しなど)、昨今の製品開発の動き・業界動向などを盛り込んでお届けいたします。

第1章 目次

第2章 イントロダクション

  • 黒色腫の概要

第3章 開発中の製品

  • パイプライン製品:開発段階別
  • パイプライン製品:地域別
  • パイプライン製品:規制経路別
  • パイプライン製品:認証時期別 (推定)
  • 現在進行中の治験

第4章 黒色腫用診断機器:開発中のパイプライン製品 (企業別)

  • 黒色腫治療薬の開発企業:パイプライン製品 (開発段階別)
  • 黒色腫治療薬:開発段階別のパイプライン製品の一覧

第5章 黒色腫用診断機器の開発企業・製品の概要

  • Abbott Diagnostics
    • パイプライン製品および進行中の治験の概要
  • Adaptive Biotechnologies Corporation
  • Advanced Cell Diagnostics, Inc.
  • Agilent Technologies, Inc.
  • BioMarker Strategies, LLC
  • Biosceptre (Aust) Pty Ltd
  • Boston University
  • Ceres Nanosciences, Inc.
  • Dana-Farber Cancer Institute, Inc.
  • Digna Biotech, S.L.
  • Exosomics Siena SpA
  • Genomic Health, Inc.
  • Hospital Universitario Cruces
  • HTG Molecular Diagnostics, Inc.
  • ImmunID Technologies
  • InterGenetics Incorporated
  • IV Diagnostics, Inc.
  • Louisville Bioscience, Inc.
  • MDNA Life Sciences, Inc.
  • Melanovus Oncology, Inc.
  • MolecularMD, Corp.
  • Myriad Genetics, Inc.
  • Orion Genomics LLC
  • Oryzon Genomics S.A.
  • Pacific Edge Limited
  • Qiagen N.V.
  • Roche Diagnostics International Ltd.
  • Rosetta Genomics, Ltd.
  • Sividon Diagnostics GmbH
  • SomaLogic, Inc.
  • The Johns Hopkins University
  • University of California, San Francisco
  • University of Colorado
  • University of Louisville
  • Zymera, Inc

第6章 黒色腫用診断機器:昨今の市場動向

第7章 付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GDME0078EPD

GlobalData's Medical Devices sector report, "Melanoma - Pipeline Review, 2015" provides an overview of Melanoma diagnostic tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Melanoma diagnostic tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Melanoma diagnostic tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Melanoma diagnostic tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Melanoma diagnostic tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Melanoma Overview

3. Products under Development

  • 3.1. Melanoma - Pipeline Products by Stage of Development
  • 3.2. Melanoma - Pipeline Products by Territory
  • 3.3. Melanoma - Pipeline Products by Regulatory Path
  • 3.4. Melanoma - Pipeline Products by Estimated Approval Date
  • 3.5. Melanoma - Ongoing Clinical Trials

4. Melanoma - Pipeline Products under Development by Companies

  • 4.1. Melanoma Companies - Pipeline Products by Stage of Development
  • 4.2. Melanoma - Pipeline Products by Stage of Development

5. Melanoma Companies and Product Overview

  • 5.1. Abbott Diagnostics Company Overview
    • 5.1.1. Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
  • 5.2. Adaptive Biotechnologies Corporation Company Overview
    • 5.2.1. Adaptive Biotechnologies Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • 5.3. Advanced Cell Diagnostics, Inc. Company Overview
    • 5.3.1. Advanced Cell Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.4. Agilent Technologies, Inc. Company Overview
    • 5.4.1. Agilent Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.5. BioMarker Strategies, LLC Company Overview
    • 5.5.1. BioMarker Strategies, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • 5.6. Biosceptre (Aust) Pty Ltd Company Overview
    • 5.6.1. Biosceptre (Aust) Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • 5.7. Boston University Company Overview
    • 5.7.1. Boston University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.8. Ceres Nanosciences, Inc. Company Overview
    • 5.8.1. Ceres Nanosciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.9. Dana-Farber Cancer Institute, Inc. Company Overview
    • 5.9.1. Dana-Farber Cancer Institute, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.10. Digna Biotech, S.L. Company Overview
    • 5.10.1. Digna Biotech, S.L. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.11. Exosomics Siena SpA Company Overview
    • 5.11.1. Exosomics Siena SpA Pipeline Products & Ongoing Clinical Trials Overview
  • 5.12. Genomic Health, Inc. Company Overview
    • 5.12.1. Genomic Health, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.13. Hospital Universitario Cruces Company Overview
    • 5.13.1. Hospital Universitario Cruces Pipeline Products & Ongoing Clinical Trials Overview
  • 5.14. HTG Molecular Diagnostics, Inc. Company Overview
    • 5.14.1. HTG Molecular Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.15. ImmunID Technologies Company Overview
    • 5.15.1. ImmunID Technologies Pipeline Products & Ongoing Clinical Trials Overview
  • 5.16. InterGenetics Incorporated Company Overview
    • 5.16.1. InterGenetics Incorporated Pipeline Products & Ongoing Clinical Trials Overview
  • 5.17. IV Diagnostics, Inc. Company Overview
    • 5.17.1. IV Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.18. Louisville Bioscience, Inc. Company Overview
    • 5.18.1. Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.19. MDNA Life Sciences, Inc. Company Overview
    • 5.19.1. MDNA Life Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.20. Melanovus Oncology, Inc. Company Overview
    • 5.20.1. Melanovus Oncology, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.21. MolecularMD, Corp. Company Overview
    • 5.21.1. MolecularMD, Corp. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.22. Myriad Genetics, Inc. Company Overview
    • 5.22.1. Myriad Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.23. Orion Genomics LLC Company Overview
    • 5.23.1. Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview
  • 5.24. Oryzon Genomics S.A. Company Overview
    • 5.24.1. Oryzon Genomics S.A. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.25. Pacific Edge Limited Company Overview
    • 5.25.1. Pacific Edge Limited Pipeline Products & Ongoing Clinical Trials Overview
  • 5.26. Qiagen N.V. Company Overview
    • 5.26.1. Qiagen N.V. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.27. Roche Diagnostics International Ltd. Company Overview
    • 5.27.1. Roche Diagnostics International Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.28. Rosetta Genomics, Ltd. Company Overview
    • 5.28.1. Rosetta Genomics, Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.29. Sividon Diagnostics GmbH Company Overview
    • 5.29.1. Sividon Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • 5.30. SomaLogic, Inc. Company Overview
    • 5.30.1. SomaLogic, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • 5.31. The Johns Hopkins University Company Overview
    • 5.31.1. The Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview
  • 5.32. University of California, San Francisco Company Overview
    • 5.32.1. University of California, San Francisco Pipeline Products & Ongoing Clinical Trials Overview
  • 5.33. University of Colorado Company Overview
    • 5.33.1. University of Colorado Pipeline Products & Ongoing Clinical Trials Overview
  • 5.34. University of Louisville Company Overview
    • 5.34.1. University of Louisville Pipeline Products & Ongoing Clinical Trials Overview
  • 5.35. Zymera, Inc Company Overview
    • 5.35.1. Zymera, Inc Pipeline Products & Ongoing Clinical Trials Overview

6. Melanoma- Recent Developments

7. Appendix

  • 7.1. Methodology
  • 7.2. About GlobalData
  • 7.3. Contact Us
  • 7.4. Disclaimer

List of Tables

  • Table 1: Melanoma - Pipeline Products by Stage of Development
  • Table 2: Melanoma - Pipeline Products by Territory
  • Table 3: Melanoma - Pipeline Products by Regulatory Path
  • Table 4: Melanoma - Pipeline Products by Estimated Approval Date
  • Table 5: Melanoma - Ongoing Clinical Trials
  • Table 6: Melanoma Companies - Pipeline Products by Stage of Development
  • Table 7: Melanoma - Pipeline Products by Stage of Development
  • Table 8: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview
  • Table 9: MAGE-A3 Companion Skin Cancer Assay - Product Status
  • Table 10: MAGE-A3 Companion Skin Cancer Assay - Product Description
  • Table 11: MAGE-A3 Skin Cancer Assay - Product Status
  • Table 12: MAGE-A3 Skin Cancer Assay - Product Description
  • Table 13: MYB Companion Diagnostic Assay - Melanoma - Product Status
  • Table 14: MYB Companion Diagnostic Assay - Melanoma - Product Description
  • Table 15: Adaptive Biotechnologies Corporation Pipeline Products & Ongoing Clinical Trials Overview
  • Table 16: Companion Diagnostic Test - Melanoma Cancer - Product Status
  • Table 17: Companion Diagnostic Test - Melanoma Cancer - Product Description
  • Table 18: Advanced Cell Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 19: RNAscope MELA - Product Status
  • Table 20: RNAscope MELA - Product Description
  • Table 21: Agilent Technologies, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 22: MK-3475 Companion Diagnostic Test - Product Status
  • Table 23: MK-3475 Companion Diagnostic Test - Product Description
  • Table 24: BioMarker Strategies, LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 25: Ex Vivo Biomarker Test - Melanoma - Product Status
  • Table 26: Ex Vivo Biomarker Test - Melanoma - Product Description
  • Table 27: PathMAP - Product Status
  • Table 28: PathMAP - Product Description
  • Table 29: Biosceptre (Aust) Pty Ltd Pipeline Products & Ongoing Clinical Trials Overview
  • Table 30: Skin Cancer IHC Diagnostic Test - Product Status
  • Table 31: Skin Cancer IHC Diagnostic Test - Product Description
  • Table 32: Boston University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 33: Microfluidic Chip - Melanoma - Product Status
  • Table 34: Microfluidic Chip - Melanoma - Product Description
  • Table 35: Ceres Nanosciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 36: Melanoma Skin Patch Sweat Test - Product Status
  • Table 37: Melanoma Skin Patch Sweat Test - Product Description
  • Table 38: Dana-Farber Cancer Institute, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 39: Biomarker Test For Immune Checkpoint Inhibitor Therapy - Product Status
  • Table 40: Biomarker Test For Immune Checkpoint Inhibitor Therapy - Product Description
  • Table 41: Digna Biotech, S.L. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 42: Melanoma Test - Product Status
  • Table 43: Melanoma Test - Product Description
  • Table 44: Exosomics Siena SpA Pipeline Products & Ongoing Clinical Trials Overview
  • Table 45: EXOTEST Melanoma - Product Status
  • Table 46: EXOTEST Melanoma - Product Description
  • Table 47: Genomic Health, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 48: Prognostic Test - Melanoma - Product Status
  • Table 49: Prognostic Test - Melanoma - Product Description
  • Table 50: Hospital Universitario Cruces Pipeline Products & Ongoing Clinical Trials Overview
  • Table 51: Diagnostic Assay - Melanoma - Product Status
  • Table 52: Diagnostic Assay - Melanoma - Product Description
  • Table 53: HTG Molecular Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 54: Diagnostic Test - Melanoma - Product Status
  • Table 55: Diagnostic Test - Melanoma - Product Description
  • Table 56: ImmunID Technologies Pipeline Products & Ongoing Clinical Trials Overview
  • Table 57: ImmunTraCkeR - Metastatic Melanoma - Product Status
  • Table 58: ImmunTraCkeR - Metastatic Melanoma - Product Description
  • Table 59: ImmunID Technologies - Ongoing Clinical Trials Overview
  • Table 60: ImmunTraCkeR - Metastatic Melanoma - Multicenter Clinical Study to Assess the Use of Immune Competence Profiles evaluated by ImmunTracker in Metastatic Melanoma Subjects Treated with an Immune Checkpoint Inhibitor
  • Table 61: InterGenetics Incorporated Pipeline Products & Ongoing Clinical Trials Overview
  • Table 62: OncoVue Skin - Product Status
  • Table 63: OncoVue Skin - Product Description
  • Table 64: IV Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 65: IVDiagnostics Diagnostic Test - Melanoma - Product Status
  • Table 66: IVDiagnostics Diagnostic Test - Melanoma - Product Description
  • Table 67: Louisville Bioscience, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 68: Melanoma Remission pT Test - Product Status
  • Table 69: Melanoma Remission pT Test - Product Description
  • Table 70: MDNA Life Sciences, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 71: Diagnostic Test - Melanoma - Product Status
  • Table 72: Diagnostic Test - Melanoma - Product Description
  • Table 73: Melanovus Oncology, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 74: Companion Diagnostic Test - Melanoma - Product Status
  • Table 75: Companion Diagnostic Test - Melanoma - Product Description
  • Table 76: MolecularMD, Corp. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 77: Diagnostic Assay - Melanoma - Product Status
  • Table 78: Diagnostic Assay - Melanoma - Product Description
  • Table 79: Myriad Genetics, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 80: myPath Melanoma - Product Status
  • Table 81: myPath Melanoma - Product Description
  • Table 82: Orion Genomics LLC Pipeline Products & Ongoing Clinical Trials Overview
  • Table 83: Diagnostic Assay - Melanoma - Product Status
  • Table 84: Diagnostic Assay - Melanoma - Product Description
  • Table 85: Oryzon Genomics S.A. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 86: Diagnostic Assay - Melanoma Cancer - Product Status
  • Table 87: Diagnostic Assay - Melanoma Cancer - Product Description
  • Table 88: Prognostic Assay - Melanoma Cancer - Product Status
  • Table 89: Prognostic Assay - Melanoma Cancer - Product Description
  • Table 90: Pacific Edge Limited Pipeline Products & Ongoing Clinical Trials Overview
  • Table 91: Prognostic Assay - Melanoma - Product Status
  • Table 92: Prognostic Assay - Melanoma - Product Description
  • Table 93: Qiagen N.V. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 94: NRAS Assay-Melanoma - Product Status
  • Table 95: NRAS Assay-Melanoma - Product Description
  • Table 96: Roche Diagnostics International Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 97: ETBR ADC Companion Diagnostic Test - Product Status
  • Table 98: ETBR ADC Companion Diagnostic Test - Product Description
  • Table 99: PDL1+Zelboraf Companion Diagnostic Test - Product Status
  • Table 100: PDL1+Zelboraf Companion Diagnostic Test - Product Description
  • Table 101: Zelboraf Companion Diagnostic Test - Metastatic Melanoma - Product Status
  • Table 102: Zelboraf Companion Diagnostic Test - Metastatic Melanoma - Product Description
  • Table 103: Rosetta Genomics, Ltd. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 104: Diagnostic Test - Melanoma - Product Status
  • Table 105: Diagnostic Test - Melanoma - Product Description
  • Table 106: Sividon Diagnostics GmbH Pipeline Products & Ongoing Clinical Trials Overview
  • Table 107: Diagnostic Assay - Melanoma - Product Status
  • Table 108: Diagnostic Assay - Melanoma - Product Description
  • Table 109: SomaLogic, Inc. Pipeline Products & Ongoing Clinical Trials Overview
  • Table 110: Diagnostic Test - Melanoma - Product Status
  • Table 111: Diagnostic Test - Melanoma - Product Description
  • Table 112: The Johns Hopkins University Pipeline Products & Ongoing Clinical Trials Overview
  • Table 113: Biomarker Based Diagnostic Assay - Melanoma - Product Status
  • Table 114: Biomarker Based Diagnostic Assay - Melanoma - Product Description
  • Table 115: Diagnostic Assay - Metastatic Melanoma - Product Status
  • Table 116: Diagnostic Assay - Metastatic Melanoma - Product Description
  • Table 117: University of California, San Francisco Pipeline Products & Ongoing Clinical Trials Overview
  • Table 118: Diagnostic Assay - Uveal Melanoma - Product Status
  • Table 119: Diagnostic Assay - Uveal Melanoma - Product Description
  • Table 120: University of Colorado Pipeline Products & Ongoing Clinical Trials Overview
  • Table 121: Biomarker Test - BRAF Mutations - Product Status
  • Table 122: Biomarker Test - BRAF Mutations - Product Description
  • Table 123: University of Louisville Pipeline Products & Ongoing Clinical Trials Overview
  • Table 124: Melanoma Sentinel Lymph Node Biomarker Test - Product Status
  • Table 125: Melanoma Sentinel Lymph Node Biomarker Test - Product Description
  • Table 126: Zymera, Inc Pipeline Products & Ongoing Clinical Trials Overview
  • Table 127: Prognostic Assay - Melanoma - Product Status
  • Table 128: Prognostic Assay - Melanoma - Product Description
  • Table 129: Glossary

List of Figures

  • Figure 1: Melanoma - Pipeline Products by Stage of Development
  • Figure 2: Melanoma - Pipeline Products by Territory
  • Figure 3: Melanoma - Pipeline Products by Regulatory Path
  • Figure 4: Melanoma - Pipeline Products by Estimated Approval Date
  • Figure 5: Melanoma - Ongoing Clinical Trials
Back to Top